Kronos Bio, Inc. ( (KRON) ) has released its Q4 earnings. Here is a breakdown of the information Kronos Bio, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kronos Bio, Inc. is a biopharmaceutical company focused on developing small molecule therapeutics targeting deregulated transcription, a key factor in cancer and autoimmune diseases, with operations in San Mateo, California, and a research facility in Cambridge, Massachusetts. In its latest earnings report, Kronos Bio disclosed its financial performance for the fourth quarter and full year of 2024, highlighting significant financial metrics and strategic evaluations. The company reported cash, cash equivalents, and investments totaling $112.4 million as of the end of 2024. Research and development expenses for the year amounted to $48.7 million, while general and administrative expenses reached $24.6 million. Notably, the company faced impairment and restructuring charges of $29.5 million for the year. Kronos Bio’s net loss for 2024 was $86.1 million, translating to a loss of $1.43 per share. As the company explores potential strategic alternatives to maximize stockholder value, its management remains focused on evaluating various options, including acquisitions and mergers. While the outcome of these evaluations remains uncertain, Kronos Bio continues to navigate its strategic path forward.